year 15, Issue 3 (May - Jun 2021)
Iran J Med Microbiol 2021, 15(3): 266-280 |
Back to browse issues page
1- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , amirmozafari@yahoo.com
2- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , amirmozafari@yahoo.com
Abstract: (4889 Views)
Background and Objective: Acinetobacter baumannii is considered to be a re-emerging causative agent of nosocomial infections. There is a significant relation between pathogenicity of this bacterium and the numerous virulence factors. The purpose of this study was to investigate nine virulence factor genes in A. baumannii isolates derived from hospitalized patients.
Materials and Methods: A total of 50 A. baumannii isolates were recovered from patients with pneumonia in Imam Khomeini Hospital, Tehran, Iran. Following biochemical and microbiological identification of the bacteria, Multiplex PCR was performed for basD, plD, csuA genes, surA, pbpG, bfmR genes, and bap, ompA genes using specific sets of primers which were specifically designed for this study. The espA was identified separately by a Uniplex PCR assay. All amplified DNA fragments were sequenced for the products’ confirmation.
Results: Among the 50 clinical isolates of A. baumannii studied, bfmR and pbpG genes were reported in all samples (100%), bap, plD, surA, and csuA genes were collected from 49 samples (98%), 48 (96%) of these isolates had ompA and basD genes, and espA gene was observed in only five isolates (10%).
Conclusion: According to this study results, virulence factors genes in clinical A. baumannii have a prevalence rate more than 90%. Additionally, the high incidence rate of those genes related to biofilm formation indicates that most clinical strains have the ability to form biofilm structures.
Keywords: Acinetobacter baumannii, Multiplex Polymerase Chain Reaction, Pneumonia, Virulence Factors
Type of Study: Original Research Article |
Subject:
Medical Bacteriology
Received: 2021/01/4 | Accepted: 2021/02/13 | ePublished: 2021/06/28
Received: 2021/01/4 | Accepted: 2021/02/13 | ePublished: 2021/06/28
References
1. Eliopoulos, G.M., L.L. Maragakis, and T.M. Perl, Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis, 2008. 46(8): 1254-63. [DOI:10.1086/529198] [PMID]
2. Jeon, B- C, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea. J Clin Microbiol, 2005. 43(5): 2241-5 [DOI:10.1128/JCM.43.5.2241-2245.2005] [PMID] [PMCID]
3. Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, Richet H. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med. 1998 Aug 1;129(3):182-9. [DOI:10.7326/0003-4819-129-3-199808010-00003] [PMID]
4. Dijkshoorn, L., A. Nemec, and H. Seifert, An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, 2007. 5(12): 939-51. [DOI:10.1038/nrmicro1789] [PMID]
5. Thummeepak, R., Phattaraporn Kongthai, Udomluk Leungtongkam, Sutthirat Sitthisak. Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clinical isolates. Int Microbiol, 2016. 19(2): 121-9
6. Cerqueira, G.M. and A.Y. Peleg, Insights into Acinetobacter baumannii pathogenicity. IUBMB life, 2011. 63(12): 1055-60. [DOI:10.1002/iub.533] [PMID]
7. Chang-Ro Lee, Jung Hun Lee, Moonhee Park , Kwang Seung Park, Il Kwon Bae, Young Bae Kim, et al., Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol, 2017. 7: p. 55. [DOI:10.3389/fcimb.2017.00055]
8. Song, W.Y., Jeong D, Kim J, Lee MW, Oh MH, Kim HJ, et al., Key structural elements for cellular uptake of acinetobactin, a major siderophore of Acinetobacter Baumannii. Org Lett, 2017. 19(3): 500-3 [DOI:10.1021/acs.orglett.6b03671] [PMID]
9. Maryam R, Golnaz YZ, Mojgan O, Malihe T, Nour A. Identification of five phylogenic groups of carbapenemase (bla OXA-23, 24, 51, 58,143) in Acinetobacter baumannii strains isolated from clinical samples in Iran by multiplex PCR. Der Pharma Chemica. 2015;7(7):11-6.
10. Jane F. Turton , Neil Woodford, Judith Glover, Susannah Yarde, Mary E. Kaufmann, Tyrone L. Pitt, Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol, 2006. 44(8): 2974-6. [DOI:10.1128/JCM.01021-06] [PMID] [PMCID]
11. Chun-Chieh Tseng, Yun-Hsuan Tsai, Anren Hu, Je-Wen Liou, Kai-Chih Chang ., Altered susceptibility to the bactericidal effect of photocatalytic oxidation by TiO 2 is related to colistin resistance development in Acinetobacter baumannii. Appl Microbiol Biotechnol, 2016. 100(19): 8549-8561. [DOI:10.1007/s00253-016-7654-x] [PMID]
12. Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg A, The mechanisms of disease caused by Acinetobacter baumannii. Front Microbiol, 2019. 10: 1601. [DOI:10.3389/fmicb.2019.01601] [PMID] [PMCID]
13. Longo, F., C. Vuotto, and G. Donelli, Biofilm formation in Acinetobacter baumannii. New Microbiol, 2014. 37(2):119-27.
14. Yang C-H, Su P-W, Moi S-H, Chuang L-Y , Biofilm formation in Acinetobacter Baumannii: genotype-phenotype correlation. Molecules, 2019. 24(10): 1849. [DOI:10.3390/molecules24101849] [PMID] [PMCID]
15. Liu C, Chang Y, Xu Y, Luo Y, Wu L, Mei Z ,et al., Distribution of virulence-associated genes and antimicrobial susceptibility in clinical Acinetobacter baumannii isolates. Oncotarget, 2018. 9(31): 21663. [DOI:10.18632/oncotarget.24651] [PMID] [PMCID]
16. Fallah, A, Rezaee MA, Hasani A, Barhaghi MHS, Kafil HS et al., Frequency of bap and cpaA virulence genes in drug resistant clinical isolates of Acinetobacter baumannii and their role in biofilm formation. Iran J Basic Med Sci, 2017. 20(8): 849
17. Zeighami H, Valadkhani F, Shapouri R, Samadi E, Haghi F, Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. BMC Infect Dis, 2019. 19(1): 629. [DOI:10.1186/s12879-019-4272-0] [PMID] [PMCID]
18. Bardbari A.M, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates. Microb Pathog, 2017. 108: 122-8. [DOI:10.1016/j.micpath.2017.04.039] [PMID]
19. alib SS, Abdulrahman TR, Ali SH. Detection of Some Biofilm Genes Related with Multidrug-Resistant in Acinobacter baumannii Isolated from Clinical Isolates. Iraqi J Med Sci, 2018. 16(4): 430-8.
20. McConnell, M.J., L. Actis, and J. Pachón, Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013. 37(2): 130-55. [DOI:10.1111/j.1574-6976.2012.00344.x] [PMID]
21. Yoon E-J, Kim D, Lee H, Lee HS, Shin JH, Uh Y, et al., Counter clinical prognoses of patients with bloodstream infections between causative Acinetobacter baumannii clones ST191 and ST451 belonging to the international clonal lineage II. Front Public Health, 2019. 7: 233. [DOI:10.3389/fpubh.2019.00233] [PMID] [PMCID]
22. Jacobs, A.C., Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, et al., Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun, 2010. 78(5): 1952-62. [DOI:10.1128/IAI.00889-09] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |